SIRT7 as a context-dependent biomarker and therapeutic target: Insights from a pan-cancer study
Fig 7
Survival analysis of SIRT7 expression and immune cell infiltration impact on patient outcomes in (A) Glioblastoma Multiforme (GBM) CD8 + , (B) Kidney Renal Papillary Cell Carcinoma (KIRP) CD8 + , (C) Uveal Melanoma (UVM) CD8 + , (D) Lower Grade Glioma (LGG) CD4 + , and (E) Lower Grade Glioma (LGG) B-Cell Populations (Source: TIMER2).